Inhibrx Sets Four Oncology Data Presentations Across Three Meetings
Image
San Diego – – October 13, 2026 -- Inhibrx Biosciences (Nasdaq: INBX) will present phase 2 data on both clinical-stage candidates in its pipeline in four sessions at three oncology conferences between Oct. 25 and Nov. 20, 2026.
Ordastobart phase 2 primary analysis goes to ESMO on Oct. 25
The first session is an oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid on Sunday, Oct. 25, from 8:30 to 10:00 AM CET. Lead author Jong Chul Park will present the phase 2 primary analysis of HexAgon-HN, a phase 2/3 study of the hexavalent OX40 agonist ordastobart (INBRX-106) combined with pembrolizumab. The trial covers first-line treatment of PD-L1-high recurrent/metastatic head and neck squamous cell carcinoma.